Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:00460'
s Days Payable Range Over the Past 10 Years
Min: 21.94 Med: 61.15 Max: 138.98
Current: 135.3
During the past 13 years, Sihuan Pharmaceutical Holdings Group's highest Days Payable was 138.98. The lowest was 21.94. And the median was 61.15.
HKSE:00460's Days Payable is ranked better than 70.55% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs HKSE:00460: 135.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group Days Payable Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sihuan Pharmaceutical Holdings Group Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's Days Payable falls into.
Sihuan Pharmaceutical Holdings Group Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group (HKSE:00460) has a Days Payable of 142.94 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. This is 134% above median its historical median of 61.15. Over the past decade, Sihuan Pharmaceutical Holdings Group's Days Payable has ranged from 21.94 to 138.98. According to the industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #273 out of 927 companies in the Drug Manufacturers industry, placing it in the top 29.4%.
Is Sihuan Pharmaceutical Holdings Group's Days Payable too high?
Sihuan Pharmaceutical Holdings Group's current Days Payable of 142.94 is 134% above median its 10-year median of 61.15. Over the past 10 years, this metric has ranged from a low of 21.94 to a high of 138.98. The Drug Manufacturers industry median Days Payable is 90.38. Sihuan Pharmaceutical Holdings Group's value of 142.94 is 58.2% above this industry median. Based on the distribution chart, Sihuan Pharmaceutical Holdings Group ranks #273 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #273 out of 927 companies for Days Payable. This puts Sihuan Pharmaceutical Holdings Group in the upper half of its industry. The industry median Days Payable is 90.38. Sihuan Pharmaceutical Holdings Group's value of 142.94 is 58.2% above this benchmark. Historically, Sihuan Pharmaceutical Holdings Group's own Days Payable has ranged from 21.94 to 138.98 over the past decade. While the company's 10-year median is 61.15 vs. the industry median of 90.38, Sihuan Pharmaceutical Holdings Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sihuan Pharmaceutical Holdings Group's current Days Payable of 142.94 is 58.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sihuan Pharmaceutical Holdings Group's current Days Payable is 142.94, which is 134% above median its own 10-year median of 61.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (HKSE:00460) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$1.18, compared to a current price of HK$0.93 — trading 21.2% below its estimated fair value. The current Days Payable is 142.94, which is 134% above median its 10-year median of 61.15 and 58.2% above the Drug Manufacturers industry median of 90.38. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (HKSE:00460), the current Days Payable is 142.94 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sihuan Pharmaceutical Holdings Group (HKSE:00460) Overvalued in 2026?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued.
The current stock price of HK$0.93 is trading 21.2% below its estimated GF Value™ of HK$1.18.
GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.
Key valuation signals for HKSE:00460:
Days Payable: 142.94 (134% above median its 10-year median of 61.15)
GF Value™: HK$1.18 vs. price of HK$0.93 (21.2% below fair value)
Industry Position: 58.2% above the Drug Manufacturers median (#273 of 927)
No single metric tells the full story. See the HKSE:00460 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sihuan Pharmaceutical Holdings Group Business Description
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
79GF Score
Get the complete analysis for HKSE:00460
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00460 has been successfully added to your 
